ArticleBMC cardiovascular disorders2026
Semaglutide in non-diabetic obese Chinese patients with acute coronary syndrome: a multicenter retrospective study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis study aimed to assess clinical benefits of semaglutide for East Asian non-diabetic obese patients with ACS who have undergone percutaneous coronary intervention (PCI) .
methodThis was a multicenter retrospective cohort study. A total of 344 non-diabetic obese patients with ACS who underwent PCI at three hospitals from May 2020 to December 2024 were enrolled (semaglutide group:112 patients, control group: 232 patients). Propensity score matching (PSM) was performed to balance the baseline data between the two groups. The primary endpoint was 6-month major adverse cardiovascular events (MACE), and secondary endpoints included dynamic changes in cardiac troponin I (cTnI) and alterations in metabolic and left ventricular ejection fraction (LVEF) at 6-month follow-up.
resultsAfter PSM, compared with the control group, the semaglutide group had lower rates of the 6-month MACE (11.6% vs. 23.2%, p = 0.034) and unplanned revascularization (4.7% vs. 13.4%, p = 0.033), and and showed faster improvement in cTnI levels. Both groups showed improvements in blood lipid profiles and LVEF post-PCI. Additionally, the semaglutide group achieved further reductions in fasting blood glucose (FBG) (5.74 ± 0.60mmol/L vs. 5.25 ± 0.43mmol/L, p < 0.0001), glycated hemoglobin (HbA1c) (5.43 ± 0.59% vs. 5.18 ± 0.50%, p = 0.016) and body mass index (BMI) (30.94 ± 1.69 kg/m²vs. 28.45 ± 2.82 kg/m², p < 0.0001). Particularly, the magnitudes of improvements in BMI (2.49 ± 3.27 kg/m²vs. 0.78 ± 2.76 kg/m², p = 0.002), FBG (0.49 ± 0.75mmol/L vs. 0.03 ± 0.83mmol/L, p < 0.0001), LDL-C (1.78 ± 1.22mmol/L vs. 0.83 ± 0.94mmol/L, p < 0.0001), TG (0.98 ± 1.02mmol/L vs. 0.63 ± 0.70mmol/L, p = 0.003) and LVEF (5.73 ± 8.07% vs. 2.66 ± 8.09%, p = 0.005) in the semaglutide group were significantly superior to those in the control group.
conclusionsSemaglutide treatment was associated with a lower 6-month MACE and favorable changes in metabolic and cardiac function in non-diabetic obese ACS patients post-PCI. These observational findings provide real-world evidence for further study. CLINICAL
trial registrationThis was a retrospective study, so clinical trial registration was not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.